Navigation Links
Are siRNA Pools Smart?

in apoptosis (Figure 4). Consistent with the cell proliferation results, the single siRNAs for each gene had similar, though non-identical effects, on caspase 3 activity. Also consistent with the cell proliferation results, the siRNA pools only partially overlapped the results of the single siRNAs (Figure 5). Examples of single and pooled siRNA results are shown in Figure 4B.

Figure 5. Overall Performance of Single siRNAs and siRNA Pools. Using the definition of a hit as a gene for which two single siRNAs produce a phenotype that is significantly different than samples transfected with a negative control siRNA, the performance of each of the single siRNAs (siRNA #1, #2, or #3) as well as the siRNA pool of the three siRNAs was compared. The combined results of screening with two (#1+#2, #1+#3, and #2+#3) or three (#1+#2+#3) individual siRNAs illustrates the higher accuracy of this strategy. Accurate predictions of hits and inaccurate predictions of hits are shown in green and orange, respectively. False negatives are shown in grey.


Single siRNAs vs. siRNA Pools: Results

To minimize experimental variability, the data comparing the effects of single and pooled siRNAs on proliferation and caspase 3 activation were generated with the same cell line and substrates at the same time. The results of the screens were used to determine the effectiveness of transfecting a series of three single siRNAs versus transfecting a pool of the three siRNAs for identifying gene "hits." The definition of a hit in our screen was a gene for which two single siRNAs gener
'"/>

Source:


Page: All 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Custom and library siRNA for efficient gene silencing
2. Custom and library siRNA for efficient gene silencing
3. Cancer siRNA Oligo Set Version 1.0
4. Library siRNA
5. Custom siRNA Oligo Synthesis Service
6. Efficient RNAi-mediated gene silencing in neuronal cells using QIAGEN siRNA and TransMessenger Transfection Reagent*
7. Quantification of siRNA Silencing Efficiency Using the LightCycler System
8. Housekeeping Genes: Universal Positive Controls in siRNA Knockdown Experiments
9. Confirming gene silencing mechanism by pGFP/GFP22 siRNA co-transfection
10. siRNA transfection optimization with the Agilent 2100 bioanalyzer
11. siRNA Design Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Are siRNA Pools Smart

(Date:5/21/2015)... 21, 2015  Prima Biomed Ltd. (NASDAQ: PBMD ... to become a leader in the development of immunotherapeutic ... the final CVac data from the Phase II CAN-003 ... for a clinically meaningful improvement in Overall Survival ("OS") ... In the group of second remission patients ...
(Date:5/21/2015)... , May 21, 2015 ... inner feelings - and those of others. Being able ... senses. Analyze and read people to anticipate their thoughts ... your deepest emotions and feelings to create unique abstract ... of responsive games. Get inside a first-person-shooter as it ...
(Date:5/21/2015)... ANGELES , May 21, 2015  CytRx ... and development company specializing in oncology, today announced ... clinical trial with aldoxorubicin for the treatment of ... brain cancer.  The open-label, multisite trial is designed ... aldoxorubicin in patients whose tumors have progressed following ...
(Date:5/21/2015)... - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: ... on the development of autologous cell therapies, announced ... Society for Cellular Therapy (ISCT) on RepliCel,s autologous ... a Phase 1/2 clinical trial.  The presentation, taking ... PM to 7:00 PM local time, will review ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3
... Dec. 13 /PRNewswire-FirstCall/ - MIGENIX Inc.,(TSX: MGI; ... for infectious,diseases, reports financial results for the ... update on its programs., UPDATE ON ... (Omigard(TM)/CPI-226/MX-226; topical cationic peptide;,prevention of catheter-related infections): ...
... 13 Ten new validation studies,were published during ... bringing the total number of studies published to ... considerable increase in interest from US and,European institutes" ... world,s,most highly respected academic medical institutions and teaching ...
... Neurocrine Biosciences,Inc. (Nasdaq: NBIX ) announced today that ... Drug Administration (FDA) indicating,that the New Drug Application (NDA) ... treatment of insomnia is approvable pending additional clinical and,preclinical ... an action letter from the FDA,stating that indiplon 5 ...
Cached Biology Technology:MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 2MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 3MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 4MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 5MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 6MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 7MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 8MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 9MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 10MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 11MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 12MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 13MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 14MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 15MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 16MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 17MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 182007 a "Record Year" for Successful Validation Studies of Simbionix Simulators 2Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA 2Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA 3
(Date:5/21/2015)... 21, 2015 According to ... Solutions (Hardware, Software, Services), by Applications (Surveillance (Airborne, ... by End-Users (Military & Defense & Commercial) - ... Imaging Market is expected to grow from $7252.0 ... at a Compound Annual Growth Rate (CAGR) of ...
(Date:5/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... 3D-ID LLC, a company engaged in biometric identification is ... technology portion of the recently awarded TIES (Technical Information ... the Army. 3D-ID LLC has a suite ... enforcement and security agencies. Gino Pereira ...
(Date:5/19/2015)... 19, 2015 Research ... addition of the  "Genetic Testing Market Outlook ... http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic Testing ... of the current and future genetic testing ... their working principles and types are covered ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2
... The body is a battle zone. Cells constantly compete with ... some cells win this competition is well known to be the ... space and survival is not as clear. A study on fruit ... by Johns Hopkins researchers describes how stem cells win this battle ...
... CORVALLIS, Ore. According to an analysis of statewide data ... $50,000 a year were more than three times likely to ... their insurance status during pregnancy and delivery. In ... likely among mothers with Medicaid coverage, and four times more ...
... the Natural History Museum believe that carnivorous behaviour in plants ... grown plants such as petunias at least part ... Victorian Gothic, Darwin and modern insights into vegetable carnivory, is ... of the Linnean Society . Carnivorous plants have caught ...
Cached Biology News:Stem cells battle for space 2Lower income women report more insurance-based discrimination during pregnancy, delivery 2Scientists think 'killer petunias' should join the ranks of carnivorous plants 2
Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048...
... raised against a partial recombinant ... SLC22A3 (NP_068812, 90 a.a. ... protein with GST tag. ... NM_021977 Protein ...
... UniPrimer-fluorescein is a hairpin primer labeled ... (fluorescein and non-fluorescent quencher) and a ... UniPrimer is identical to the UniPrimer ... System (S7901) and is provided at ...
... clear polystyrene with frosted labeling surfaces, ... cell counting. 100% integrity tested. Linkage: ... product number, created to easily match ... availability yet, please order under the ...
Biology Products: